Abstract:Welcome to the start of another year with Seminars in Thrombosis and Hemostasis (STH), this being my 16th year anniversary as Editor in Chief, so still a teenager! In contrast, 2024 marks the 50th birthday of STH, which first published in 1974.[1] A half century of publishing is a landmark worthy of celebration. We started the celebrations in 2022, when we published our first Celebratory issue.[2] A second Celebratory issue was published in 2023.[3] Both issues were rich with content of a historical nature related to the fields of thrombosis and hemostasis. The current issue represents the third in the series of historical papers. We plan to prepare a fourth and final compilation later in this year. As now standard for these "welcome" editorials, I will again sincerely thank all past and current contributors to STH over the many years, as well as to all past, current, and future Guest Editors who commit their time to advance STH, and of course the current and past Editorial teams. There has been no major overhaul of the general editorial team at the time of writing, although some adjustments will continue to occur over the coming years. However, in 2024, we do bid farewell to some of our senior editors. Professor Hau Kwaan has decided to retire from STH, after 10 years as a Senior Editor. Professor Kwaan first contributed to STH in 1979,[4] just a few years after STH began publishing, and so representing 45 years of association with this journal—a much longer tenure than my own. Also departing as Senior Editors are Anne Mett Hvas and Ton Lisman. Professor Hvas was recently appointed dean of the Faculty of Health at Aarhus University,[5] and she felt she could not commit sufficient time to continue on as a Senior Editor. Professor Hvas was a Senior Editor of STH from 2021. Ton Lisman was recently appointed as the new (co-)editor in chief of the Journal of Thrombosis and Haemostasis,[6] and thus could not remain on as a Senior Editor of STH. Professor Lisman was Senior Editor of STH from 2015. Both Anne Mett Hvas and Ton Lisman will stay on as Associate Editors of the journal, and we hope them the best for their future roles and success in the field. To help fill the void of their departure, we are 'promoting' Kristi Smock (USA) and Julie Brogaard Larsen (Denmark) from our editorial board to positions as Senior Editors. Both have contributed to several Guest Editorial positions in the past. Kristi Smock completed two issues around 'Laboratory Diagnostics' with Co-Guest Editor Robert Gosselin in 2022[7] and 2023[8], and is currently compiling a third issue with Co-Guest Editor Karen Moffat. Julie Brogaard Larsen has Co-Guest edited several past issues of STH from 2017[9] [10] [11], and is currently Co-Guest Editing her 4th issue of STH on the topic of Cancer with Tua Gyldenholm. We welcome Kristi and Julie into their new Senior Editor positions, and look forward to their further contributions to our journal. I also take this opportunity to once again thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal, and in particular, Mansi Agarwal, the current Production Editor for STH, and her production team. This annual Editorial once represented the opportunity to reflect on our journal's Impact Factor and other journal metrics. However, because of the continuing move to online publication ahead of print publication, a separate detailed editorial was published on these topics late last year.[12] In addition to detailing information on the journal's Impact Factor, in part in comparison to trends from other journals publishing in the Thrombosis and Hemostasis space, I also shared many other publication metrics. I will summarize the information on Impact Factor as follows: (1) the 2022 Impact Factor was 5.7, which marked an anticipated decrease over the 2021 Impact Factor, which was 6.938; (2) in turn, the 2021 Impact Factor for STH marked a substantive increase over the 2020 Impact Factor, which was 4.180, and the 2019 Impact Factor, which was 2.892; (3) the 2021 Impact Factor of 6.398 also represents the highest Impact Factor ever achieved by STH, and this was largely due to some highly cited papers related to COVID-19 (coronavirus disease 2019); (4) the previous highest Impact Factor (4.524) was 10 years ago in 2011; (5) in general, most thrombosis and hemostasis focused journals showed an increase in Impact Factor from 2020 to 2021, largely on the back of several highly cited COVID-19-related papers, and then a subsequent fall in 2022 due to "waning interest" in COVID-19. It should also be noted that the calculations used to generate the yearly Impact Factors have evolved over recent years to ensure better representation of online publications, which often precede print versions by several months. Indeed, some journa -Abstract Truncated-

Summing Up Pharmacological Reviews 75th Anniversary Year and a Look to the Future

Seventy-Five Years of Interactions: The Department of Physiology and Pharmacology at Karolinska Institutet and Pharmacological Reviews

Pharmacology and Precision Medicine--Preparing for the Next Era in Clinical Medicine--Editorial

The 75-Year Anniversary of the Department of Physiology and Pharmacology at Karolinska Institutet--Examples of Recent Accomplishments and Future Perspectives

The Evolution of Drug Metabolism and Disposition: A Perspective From the Editors

Introduction to the Theme "Novel Therapeutics with the Potential to Advance Health Care"

ANXIOLYTICS: Introduction to a special issue celebrating 50 years of pharmacology, biochemistry and behavior

Special Issue Celebrating the Austrian Pharmacognosy

The 125th Anniversary of Aspirin—The Story Continues

Celebrating Women in the Pharmaceutical Sciences.

Annual Advances of Integrative Pharmacology in 2018

Polypharmacy and Deprescribing in Older Adults.

Welcome to Seminars in Thrombosis and Hemostasis 2024: 50 Years of Publishing

Editorial for GPR84 pharmacology

Bibliometric development of Naunyn-Schmiedeberg's Archives of Pharmacology

The European Association for Clinical Pharmacology and Therapeutics-25 years' young and going strong

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

Acknowledgment to the Reviewers of Pharmaceutics in 2022

Biotransformation research advances – 2023 year in review

1954-2024: 70 years of histochemical research with the European Journal of Histochemistry

Acknowledgement to Referees